Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes.

Belstrøm D, Holmstrup P, Damgaard C, Borch TS, Skjødt MO, Bendtzen K, Nielsen CH.

Infect Immun. 2011 Apr;79(4):1559-65. doi: 10.1128/IAI.01036-10. Epub 2011 Jan 18.

3.

Inhibition of C3 and IgG proteolysis enhances phagocytosis of Porphyromonas gingivalis.

Cutler CW, Arnold RR, Schenkein HA.

J Immunol. 1993 Dec 15;151(12):7016-29.

PMID:
8258706
4.

Complement factor D-like activity of Porphyromonas gingivalis W83.

Schenkein HA.

Oral Microbiol Immunol. 1991 Aug;6(4):216-20.

PMID:
1667434
5.
6.

Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ.

J Immunol. 1985 Sep;135(3):2005-14.

PMID:
4020137
7.
8.

Pneumococcal immune adherence to human erythrocytes.

Hament JM, van Dijk H, Fleer A, Aerts PC, Schoenmakers M, de Snoo MW, Dekker BH, Kimpen JL, Wolfs TF.

Eur J Clin Invest. 2003 Feb;33(2):169-75.

PMID:
12588292
9.

Lipoxin A₄ inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression.

Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T.

Infect Immun. 2011 Apr;79(4):1489-97. doi: 10.1128/IAI.00777-10. Epub 2011 Jan 24.

11.

Characterization of an adherence and antigenic determinant of the ArgI protease of Porphyromonas gingivalis which is present on multiple gene products.

Curtis MA, Aduse-Opoku J, Slaney JM, Rangarajan M, Booth V, Cridland J, Shepherd P.

Infect Immun. 1996 Jul;64(7):2532-9.

12.

In vitro complement activation, adherence to red blood cells and induction of mononuclear cell cytokine production by four strains of Aggregatibacter actinomycetemcomitans with different fimbriation and expression of leukotoxin.

Damgaard C, Reinholdt J, Palarasah Y, Enevold C, Nielsen C, Brimnes MK, Holmstrup P, Nielsen CH.

J Periodontal Res. 2017 Jun;52(3):485-496. doi: 10.1111/jre.12414. Epub 2016 Sep 24.

PMID:
27663487
13.

Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system.

Popadiak K, Potempa J, Riesbeck K, Blom AM.

J Immunol. 2007 Jun 1;178(11):7242-50.

15.

Characterization of T lymphocyte clones derived from Porphyromonas gingivalis infected subjects.

Gemmell E, Woodford V, Seymour GJ.

J Periodontal Res. 1996 Jan;31(1):47-56.

PMID:
8636876
16.

Anti-phagocytic role of surface fibrous structure of an invasive Porphyromonas gingivalis strain.

Miyabe H, Ishihara K, Kigure T, Okuda K.

Bull Tokyo Dent Coll. 2004 Feb;45(1):47-57.

17.

Adherence of Porphyromonas gingivalis to epithelial cells: analysis by flow cytometry.

Huard-Delcourt A, Ménard C, Du L, Pellen-Mussi P, Tricot-Doleux S, Bonnaure-Mallet M.

Eur J Oral Sci. 1998 Oct;106(5):938-44. Erratum in: Eur J Oral Sci 1998 Dec;106(6):1051.

PMID:
9786323
18.

Binding of the periodontitis associated bacterium Porphyromonas gingivalis to glycoproteins from human epithelial cells.

Hallén U, Björkner AE, Hallberg EC.

Oral Microbiol Immunol. 2008 Oct;23(5):367-71. doi: 10.1111/j.1399-302X.2008.00437.x.

PMID:
18793358
19.
20.

Monoclonal antibody against Porphyromonas gingivalis hemagglutinin inhibits hemolytic activity.

Hosogi Y, Hayakawa M, Abiko Y.

Eur J Oral Sci. 2001 Apr;109(2):109-13.

PMID:
11347654

Supplemental Content

Support Center